Abstract
Purpose To evaluate the reliability of the NIDEK Gonioscope GS-1 when used to grade the iridocorneal angle in a clinical setting.
Methods A total of 20 participants (37 eyes) who were 18 or older and had glaucoma or were glaucoma suspects were enrolled from the NYU Langone Eye Center and Bellevue Hospital. During their usual ophthalmology visit, they were consented for the study and underwent 360-degree goniophotography using the NIDEK Gonioscope GS-1. Afterwards, the three ophthalmologists separately examined the images obtained and determined the status of the iridocorneal angle in four quadrants using the Shaffer grading system. Physicians were masked to patient names and diagnoses. Inter-observer reproducibility was determined using Fleiss’ kappa statistics.
Results The interobserver reliability using Fleiss’ statistics was shown to be significant between three glaucoma specialists with fair overall agreement (Fleiss’ kappa: 0.266, p<.0001) in the interpretation of 360-degree goniophotos. Automated 360-degree goniophotography using the NIDEK Gonioscope GS-1 have quality such that they are interpreted similarly by independent expert observers. This indicates that angle investigation may be performed using this automated device and that interpretation by expert observers is likely to be similar.
Conclusion Images produced from automated 360-degree goniophotography using the NIDEK Gonioscope GS-1 are similarly interpreted amongst glaucoma specialists, thus supporting use of this technique to document and assess the anterior chamber angle in patients with, or suspected of, glaucoma and iridocorneal angle abnormalities.
Précis Automated 360-degree goniophotography using the NIDEK Gonioscope GS-1 is a reasonable tool for anterior chamber angle assessment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03715231
Clinical Protocols
https://clinicaltrials.gov/show/NCT03715231
Funding Statement
NIH: R01-EY013178, and an unrestricted grant from Research to Prevent Blindness New York, NY https://www.rpbusa.org/rpb/ (JS) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NYU Langone Health IRB irb-info{at}nyulangone.org 212-263-4110
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding: NIH: R01-EY013178, and an unrestricted grant from Research to Prevent Blindness (New York, NY)
The authors have no proprietary or commercial interest in any material discussed in this manuscript. None of the authors have any financial disclosures or conflicts of interest relevant to this study to disclose.
Data Availability
Data cannot be shared publicly because of patient protected health information. Data are available from the NYU Langone Health Institutional Data Access / Ethics Committee (contact via 212-263-4110) for researchers who meet the criteria for access to confidential data.
